CVS Health Corporation $CVS Stock Acquired by Boston Partners

CVS Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Boston Partners increased its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 28.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,614,590 shares of the pharmacy operator's stock after acquiring an additional 581,007 shares during the period. Boston Partners owned approximately 0.20% of CVS Health worth $224,044,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. BlackRock Inc. purchased a new position in CVS Health in the second quarter valued at about $12,747,462,000. State Street Corp boosted its holdings in shares of CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator's stock valued at $7,751,205,000 after buying an additional 15,604,883 shares during the period. Bank of America Corp DE raised its stake in shares of CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock worth $2,398,868,000 after buying an additional 13,836,701 shares in the last quarter. Pzena Investment Management LLC acquired a new stake in shares of CVS Health during the second quarter valued at approximately $1,217,558,000. Finally, Wellington Management Group LLP raised its holdings in shares of CVS Health by 49.8% during the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock worth $3,496,725,000 after acquiring an additional 11,233,381 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CVS Health

In other news, EVP Prem Shah purchased 23,855 shares of the company's stock in a transaction dated Friday, November 6th. The shares were acquired at an average cost of $83.89 per share, for a total transaction of $2,001,195.95. Following the completion of the purchase, the executive vice president directly owned 88,516 shares in the company, valued at $7,425,607.24. The trade was a 36.89% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.85% of the stock is currently owned by insiders.

Recent CVS Health Headlines

Investors following CVS have been watching these headlines:

CVS Health Price Performance

NYSE:CVS opened at $80.09 on Friday. The firm has a market cap of $102.47 billion, a price-to-earnings ratio of 9.32, a PEG ratio of 0.71 and a beta of 0.58. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.66 and a current ratio of 0.85. The firm's fifty day moving average is $88.69 and its two-hundred day moving average is $89.27.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share for the quarter, beating analysts' consensus estimates of $1.65 by $0.44. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The company had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. During the same quarter last year, the firm posted $1.60 EPS. The firm's revenue for the quarter was up 5.4% on a year-over-year basis. Research analysts expect that CVS Health Corporation will post 8.26 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd were issued a $0.6650 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend was Thursday, October 22nd. CVS Health's dividend payout ratio is presently 30.97%.

Analysts Set New Price Targets

CVS has been the subject of a number of research analyst reports. Argus lifted their target price on shares of CVS Health from $104.00 to $114.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. Cantor Fitzgerald reiterated a "neutral" rating on shares of CVS Health in a research report on Friday, October 9th. BMO Capital Markets set a $112.00 price objective on CVS Health in a research note on Wednesday, September 9th. Sanford C. Bernstein reiterated an "outperform" rating on shares of CVS Health in a research note on Friday, November 13th. Finally, Robert W. Baird set a $107.00 target price on CVS Health in a report on Thursday, August 6th. Twenty-three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $107.33.

View Our Latest Stock Analysis on CVS Health

About CVS Health

(Free Report)

CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.

Featured Articles

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines